抗癌藥物及抗精神藥物對肝癌細胞之毒性效應探討

肝細胞癌的治療手段不斷地被開發及研究，病人單獨服用一種標靶藥物似乎已經成了一種普遍的延緩病情的方法，但研究顯示合併用藥可達到更好的效果。本研究深入去探討抗癌藥物(Avastin, Vincristine)及抗精神藥物(Risperidone)合併後對肝細胞癌細胞株(HepG2及Huh7)存活率的影響，研究發現隨著時間以及藥物濃度的增加，即使在低劑量抗精神藥物的情況下合併抗癌藥物，也可以很有效地抑制癌細胞的生長，並且藥物間有很明顯的協同作用(synergism effect)。此外透過西方墨點法以及免疫螢光法更加確認合併用藥後可以使癌細胞走向自噬的路徑而死亡，希望這項發現可以成為日後臨床上治療肝細胞癌的新方針。

There have been extensive researches done with regards to the treatment modality of hepatocellular carcinoma. In fact, the use of targeted therapy as mono-therapy has been a conventional method to prolong the survival of the patients. However, there are also convincing evidences from researches that combination therapy could have a more superior effectiveness. This study explores the survival rate of hepatocellular cell strain (HepG2 & Huh7) with the simultaneous use of both chemotherapy (Avastin, Vincristine) and anti-psychotic (Risperidone). As a result, we have found out that this combination of drugs exhibit synergism effect, as evidenced by its commendable efficacy of inhibiting the growth of tumor cells even in low doses. Furthermore, with the use of Western Blot and immunofluorescence test, we are able to confirm the death of tumor cells via autophagy. Therefore, we hope this discovery could introduce a new perspective in the treatment of hepatocellular carcinoma in the future.